Cargando…

A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature

INTRODUCTION: Germline CHEK2 mutations are rare and have not been associated with increased risk of NSCLC. METHODS: We identified two sequential primary NSCLCs harboring distinct actionable driver alterations (EGFR E746 _S752 delinsV and CD74-ROS1) in a patient with NSCLC with a novel germline CHEK2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shannon S., Lee, Jessica K., Tukachinsky, Hanna, Schrock, Alexa B., Nagasaka, Misako, Ou, Sai-Hong Ignatius
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429789/ https://www.ncbi.nlm.nih.gov/pubmed/36061833 http://dx.doi.org/10.1016/j.jtocrr.2022.100387

Ejemplares similares

In Response to Dr. Steven Sorscher
por: Zhang, Shannon S., et al.
Publicado: (2022)

CHEK2 Pathogenic Germline Variants in Patients With NSCLC
por: Sorscher, Steven
Publicado: (2022)

A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

The First Case Report of a Patient With Oligodendroglioma Harboring CHEK2 Germline Mutation
por: Li, Xueen, et al.
Publicado: (2022)

A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review
por: Zhu, Viola W., et al.
Publicado: (2020)

How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
por: Xia, Bing, et al.
Publicado: (2020)

Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2021)

ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?
por: Nagasaka, Misako, et al.
Publicado: (2022)

Prevalence of the CHEK2 R95* germline mutation
por: Knappskog, Stian, et al.
Publicado: (2016)

Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
por: Brazel, Danielle, et al.
Publicado: (2023)

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
por: Zhu, Viola W, et al.
Publicado: (2020)

Case Report of an Adrenocortical Carcinoma Associated With Germline CHEK2 Mutation
por: Xie, Changqing, et al.
Publicado: (2018)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Germline mutation of CHEK2 in neurofibromatosis 1 and 2: Two case reports
por: Li, Qiang, et al.
Publicado: (2018)

CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate
por: Stolarova, Lenka, et al.
Publicado: (2020)

Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers
por: Toss, Angela, et al.
Publicado: (2021)

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
por: Brazel, Danielle, et al.
Publicado: (2023)

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma
por: Havranek, Ondrej, et al.
Publicado: (2015)

Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer
por: Anwar, Kaleem, et al.
Publicado: (2022)

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
por: Zhu, Viola W, et al.
Publicado: (2019)

ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk
por: Stolarova, Lenka, et al.
Publicado: (2023)

The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers
por: Mandelker, Diana, et al.
Publicado: (2019)

Recurrent Germline Mutations of CHEK2 as a New Susceptibility Gene in Patients with Pheochromocytomas and Paragangliomas
por: Gao, Yinjie, et al.
Publicado: (2021)

Case report: Two sisters with a germline CHEK2 variant and distinct endocrine neoplasias
por: Vallera, Raphaelle D., et al.
Publicado: (2022)

Further Association of Germline CHEK2 Loss-of-Function Variants with Testicular Germ Cell Tumors
por: Kirchner, Kira, et al.
Publicado: (2023)

Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
por: Klempner, Samuel J, et al.
Publicado: (2017)

A Case Report of CHEK2 and MUTYH Germline Mutations Associated With Cholangiocarcinoma in a Young Patient
por: Rehman, Obaid, et al.
Publicado: (2022)

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
por: Brazel, Danielle, et al.
Publicado: (2022)

Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2017)

CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
por: Lee, Alexandria T M, et al.
Publicado: (2023)

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
por: Brazel, Danielle, et al.
Publicado: (2023)

Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations
por: Ahn, Jeffrey, et al.
Publicado: (2023)

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
por: Zhu, Viola W, et al.
Publicado: (2018)

Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing
por: Tung, Nadine, et al.
Publicado: (2023)

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability
por: Wang, Hui, et al.
Publicado: (2022)

Rapid Disease Progression in a Patient with Advanced NSCLC Harboring a Germline MET Exon 14 Skipping Mutation: A Case Report
por: Jiao, Yang, et al.
Publicado: (2021)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t6gr7ocm0ni5qtnt26gst38s0v